Krystal Biotech (NASDAQ:KRYS) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Krystal Biotech (NASDAQ:KRYS) in a research note released on Monday, Benzinga reports. The brokerage currently has a $200.00 price target on the stock.

A number of other equities analysts also recently weighed in on the stock. Stifel Nicolaus reaffirmed a buy rating and set a $204.00 target price (up previously from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. Citigroup raised their price target on shares of Krystal Biotech from $160.00 to $195.00 and gave the company a buy rating in a research report on Tuesday, February 27th. William Blair reissued an outperform rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Finally, Guggenheim raised their target price on shares of Krystal Biotech from $130.00 to $175.00 and gave the stock a buy rating in a report on Tuesday, February 27th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, Krystal Biotech has an average rating of Buy and an average price target of $171.00.

Krystal Biotech Price Performance

KRYS stock opened at $159.05 on Monday. Krystal Biotech has a 1 year low of $82.09 and a 1 year high of $189.97. The company has a market cap of $4.54 billion, a P/E ratio of 1,988.13 and a beta of 0.85. The firm has a 50-day moving average of $162.61 and a 200 day moving average of $131.15.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, February 26th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.82. The business had revenue of $42.14 million for the quarter, compared to the consensus estimate of $27.43 million. During the same period in the prior year, the business posted ($1.25) EPS. On average, equities research analysts expect that Krystal Biotech will post 1.89 earnings per share for the current fiscal year.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, CAO Kathryn Romano sold 5,000 shares of Krystal Biotech stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $165.88, for a total value of $829,400.00. Following the sale, the chief accounting officer now directly owns 12,936 shares in the company, valued at approximately $2,145,823.68. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $170.96, for a total value of $4,274,000.00. Following the sale, the insider now directly owns 1,550,882 shares in the company, valued at approximately $265,138,786.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CAO Kathryn Romano sold 5,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total transaction of $829,400.00. Following the completion of the sale, the chief accounting officer now owns 12,936 shares in the company, valued at $2,145,823.68. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 38,087 shares of company stock worth $6,210,591. Insiders own 14.10% of the company’s stock.

Hedge Funds Weigh In On Krystal Biotech

A number of large investors have recently made changes to their positions in the company. Allspring Global Investments Holdings LLC boosted its stake in shares of Krystal Biotech by 167.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 158,425 shares of the company’s stock worth $28,189,000 after purchasing an additional 99,101 shares during the period. Hennion & Walsh Asset Management Inc. boosted its stake in shares of Krystal Biotech by 5.6% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 33,154 shares of the company’s stock worth $5,899,000 after purchasing an additional 1,756 shares during the period. Los Angeles Capital Management LLC boosted its stake in shares of Krystal Biotech by 6.6% during the 1st quarter. Los Angeles Capital Management LLC now owns 10,214 shares of the company’s stock worth $1,817,000 after purchasing an additional 629 shares during the period. Vanguard Group Inc. boosted its position in Krystal Biotech by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after buying an additional 35,632 shares during the period. Finally, Goldman Sachs Group Inc. boosted its position in Krystal Biotech by 23.7% in the 4th quarter. Goldman Sachs Group Inc. now owns 228,053 shares of the company’s stock valued at $28,292,000 after buying an additional 43,709 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).